Compare Eli Lilly And Co (LLY) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Logitech International SA — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Logitech International SA trades at $98.15 (market cap $14.46B). The key difference: Eli Lilly And Co is far larger — about 71.9× Logitech International SA's market cap, and Logitech International SA pays the higher dividend (1.63%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Logitech International SA for 92 Days on average.
| LLY | LOGI | |
|---|---|---|
Market Cap | $1.04T | $14.46B |
Volume | 3,064,878 | 349,547 |
Sector | Health | Technology |
52-Week High | $1.28K | $126.69 |
52-Week Low | $799.57 | $85.84 |
Typical Hold Time | 93 Days | 92 Days |
Enterprise Value | $1.09T | $12.79B |
Dividend Yield | 0.59% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Logitech (LOGI) trades at $98.49, down 3.61% on the day, with a neutral technical outlook and mixed analyst sentiment. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong profitability is evident with a net income margin of 16.28% and ROE of 35.29%. Recent news highlights product launches and partnerships, including new headsets and a collaboration with SEGA.
The outlook is balanced, with potential upside to the consensus price target of $107.00, supported by solid fundamentals and innovation. Risks include competitive pressures and macroeconomic sensitivity. Analyst consensus is divided, with 26.32% buy ratings, reflecting cautious optimism amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
